Vertex Pharmaceuticals said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of mutations of the ...

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") ...

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis. Alyftrek is a once-daily ...

The announcement comes directly from Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated, with the signatory on the report being Jonathan Biller, the Executive Vice President and Chief Legal Officer ...

BMO Capital lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $566 but keeps an Outperform rating on the shares. The company’s Suzetrigine Phase 2 LSR ...

Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $441 from $506 and keeps a Market Perform rating on the shares. The firm thinks suzetrigine is at least somewhat ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $535 from $600 and keeps a Buy rating on the shares after the company announced results ...

Barclays lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $418 from $509 and keeps an Equal Weight rating on the shares. The firm says the Phase 2 painful lumbosacral ...

CNBC’s Jim Cramer delivers his daily Mad Dash. Luigi Mangione, CEO killing suspect, pleads not guilty to state terror and murder charges in Manhattan court Congress ...

Dec 20 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab next-generation treatment for a rare and progressive genetic disease ...